China-based Shanghai Thederma Pharmaceuticals Co., Ltd has reportedly raised RMB 100 million (USD 14.35 million) in a Series A financing round, led by Bainuo Capital. Existing investor Hankang Capital also participated in the round. The proceeds will be used to support research and development and clinical studies for multiple autoimmune inflammatory disease therapies targeting aryl hydrocarbon receptors (AhR).
Role of AhR in Disease Regulation
AhR is a ligand-activated transcription factor that can sense a variety of endogenous and exogenous molecules, affecting biological effects. It is an important immune regulator in the human body, expressed in various tissues, particularly in the epidermis and mucous membrane. AhR-targeted therapies have applications in autoimmune inflammatory diseases involving the digestive system, respiratory system, ophthalmology, and dermatology.
Company and Leadership
Thederma Pharma is focused on developing AhR-related autoimmune inflammatory disease therapies. The company is led by Dr. Chen Genghui, who co-discovered the world’s first AhR-targeted external drug. This first-in-class drug has been approved in both China and the United States, highlighting Thederma’s innovative approach to treating autoimmune diseases.
Significance of the Funding
The Series A funding round provides Thederma Pharmaceuticals with the necessary resources to advance its pipeline of AhR-targeted therapies. This investment will help the company accelerate the development and commercialization of innovative treatments for autoimmune inflammatory diseases, potentially improving patient outcomes globally.-Fineline Info & Tech
